MA57226B1 - Méthodes de traitement d'une splénomégalie - Google Patents
Méthodes de traitement d'une splénomégalieInfo
- Publication number
- MA57226B1 MA57226B1 MA57226A MA57226A MA57226B1 MA 57226 B1 MA57226 B1 MA 57226B1 MA 57226 A MA57226 A MA 57226A MA 57226 A MA57226 A MA 57226A MA 57226 B1 MA57226 B1 MA 57226B1
- Authority
- MA
- Morocco
- Prior art keywords
- splenomegaly
- methods
- treatment
- relates
- therapeutic methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Processing Of Solid Wastes (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062958632P | 2020-01-08 | 2020-01-08 | |
| PCT/US2021/012696 WO2021142257A1 (en) | 2020-01-08 | 2021-01-08 | Methods of treating splenomegaly |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA57226A1 MA57226A1 (fr) | 2023-02-28 |
| MA57226B1 true MA57226B1 (fr) | 2023-06-28 |
Family
ID=76788747
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA57226A MA57226B1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
| MA63848A MA63848B1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
| MA69153A MA69153A1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA63848A MA63848B1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
| MA69153A MA69153A1 (fr) | 2020-01-08 | 2021-01-08 | Méthodes de traitement d'une splénomégalie |
Country Status (15)
| Country | Link |
|---|---|
| EP (2) | EP3980069A4 (https=) |
| JP (2) | JP7771064B2 (https=) |
| KR (1) | KR20220130151A (https=) |
| CN (1) | CN114423457A (https=) |
| AU (1) | AU2021205484A1 (https=) |
| BR (1) | BR112022013646A2 (https=) |
| CA (1) | CA3164063A1 (https=) |
| CO (1) | CO2022010592A2 (https=) |
| CR (1) | CR20220374A (https=) |
| IL (1) | IL294582A (https=) |
| JO (1) | JOP20220168A1 (https=) |
| MA (3) | MA57226B1 (https=) |
| MX (1) | MX2022008490A (https=) |
| TN (1) | TN2022000185A1 (https=) |
| WO (1) | WO2021142257A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240024314A1 (en) | 2020-01-08 | 2024-01-25 | Telios Pharma, Inc. | Methods of Treating Splenomegaly |
| TN2022000185A1 (en) * | 2020-01-08 | 2024-04-01 | Telios Pharma Inc | Methods of treating splenomegaly |
| US20240293403A1 (en) * | 2021-06-16 | 2024-09-05 | Telios Pharma, Inc. | Treatment of Symptoms Associated with Myeloproliferative Neoplasms |
| WO2023071973A1 (en) * | 2021-10-26 | 2023-05-04 | Shenzhen Targetrx, Inc. | Fused bicyclic compound for inhibiting activity of tyrosine kinase |
| WO2024041614A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene Switzerland Gmbh | Solid forms comprising (s) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetrahydropyrazolo [1, 5-a] pyrimidine-3-carboxamide, and oxalic acid, compositions and methods of use thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015057992A1 (en) * | 2013-10-16 | 2015-04-23 | Izumi Raquel | Btk inhibitors for hematopoietic mobilization |
| WO2015081127A2 (en) * | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
| PL3179991T3 (pl) * | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| WO2016054491A1 (en) * | 2014-10-03 | 2016-04-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
| BR112020025881A2 (pt) * | 2018-06-19 | 2021-03-23 | Merck Patent Gmbh | formas cristalinas de 1-(4-{[6-amino-5-(4-fenóxi-fenil)-pirimidin-4-ilamino]-metil}-4-fluoro-piperidin-1-il)-propenona, formas de sal do mesmo e processos para obter as mesmas |
| CN109942835A (zh) * | 2019-03-27 | 2019-06-28 | 广州楹鼎生物科技有限公司 | 一种催化分解木质纤维原料的方法 |
| TW202128156A (zh) * | 2019-11-14 | 2021-08-01 | 美商夸格智財控股有限公司 | 用於癌症治療之btk抑制劑及mdm2抑制劑之組合 |
| TN2022000185A1 (en) * | 2020-01-08 | 2024-04-01 | Telios Pharma Inc | Methods of treating splenomegaly |
-
2021
- 2021-01-08 TN TNP/2022/000185A patent/TN2022000185A1/en unknown
- 2021-01-08 MA MA57226A patent/MA57226B1/fr unknown
- 2021-01-08 MX MX2022008490A patent/MX2022008490A/es unknown
- 2021-01-08 MA MA63848A patent/MA63848B1/fr unknown
- 2021-01-08 CA CA3164063A patent/CA3164063A1/en active Pending
- 2021-01-08 EP EP21738476.7A patent/EP3980069A4/en active Pending
- 2021-01-08 WO PCT/US2021/012696 patent/WO2021142257A1/en not_active Ceased
- 2021-01-08 AU AU2021205484A patent/AU2021205484A1/en active Pending
- 2021-01-08 MA MA69153A patent/MA69153A1/fr unknown
- 2021-01-08 CN CN202180004918.1A patent/CN114423457A/zh active Pending
- 2021-01-08 IL IL294582A patent/IL294582A/en unknown
- 2021-01-08 CR CR20220374A patent/CR20220374A/es unknown
- 2021-01-08 BR BR112022013646A patent/BR112022013646A2/pt unknown
- 2021-01-08 KR KR1020227027305A patent/KR20220130151A/ko active Pending
- 2021-01-08 EP EP22150344.4A patent/EP4000624A1/en active Pending
- 2021-01-08 JP JP2022542216A patent/JP7771064B2/ja active Active
-
2022
- 2022-07-07 JO JOP/2022/0168A patent/JOP20220168A1/ar unknown
- 2022-07-28 CO CONC2022/0010592A patent/CO2022010592A2/es unknown
-
2025
- 2025-11-05 JP JP2025186533A patent/JP2026027353A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MA57226A1 (fr) | 2023-02-28 |
| JP2023509968A (ja) | 2023-03-10 |
| CO2022010592A2 (es) | 2022-10-31 |
| EP3980069A4 (en) | 2022-08-17 |
| MX2022008490A (es) | 2022-10-13 |
| CN114423457A (zh) | 2022-04-29 |
| AU2021205484A1 (en) | 2022-08-18 |
| JOP20220168A1 (ar) | 2023-01-30 |
| KR20220130151A (ko) | 2022-09-26 |
| WO2021142257A1 (en) | 2021-07-15 |
| EP4000624A1 (en) | 2022-05-25 |
| CA3164063A1 (en) | 2021-07-15 |
| BR112022013646A2 (pt) | 2022-10-04 |
| JP7771064B2 (ja) | 2025-11-17 |
| TN2022000185A1 (en) | 2024-04-01 |
| IL294582A (en) | 2022-09-01 |
| MA69153A1 (fr) | 2025-07-31 |
| EP3980069A1 (en) | 2022-04-13 |
| JP2026027353A (ja) | 2026-02-18 |
| MA63848B1 (fr) | 2024-10-31 |
| MA63848A1 (fr) | 2024-04-30 |
| CR20220374A (es) | 2023-01-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA57226B1 (fr) | Méthodes de traitement d'une splénomégalie | |
| MA51918A (fr) | Compositions et méthodes de traitement d'une hypoacousie non associée à l'âge chez un sujet humain | |
| MA54227B1 (fr) | Méthodes de traitement de la fibrose kystique | |
| MA57825B1 (fr) | Tétrahydrofuranes substitués en tant que modulateurs de canaux sodiques | |
| MA52861B1 (fr) | Méthodes et compositions pour le traitement de l'apnée du sommeil ou le ronflement simple | |
| MA44764A (fr) | Méthodes de traitement de patients présentant une hypercholestérolémie familiale | |
| ATE355374T1 (de) | Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen | |
| MA52219B1 (fr) | Traitement de l'hidradénite suppurée à l'aide d'inhibiteurs de jak | |
| MA37829A1 (fr) | Combinaisons pharmaceutiques comprenant un inhibiteur de b-raf, un inhibiteur d'egfr et facultativement un inhibiteur de pi3k alpha | |
| MA30413B1 (fr) | Nouvelles compositions pharmaceutiques faiblement dosees contenant du nimesulide, leur preparation et utilisation | |
| EP2331095A4 (en) | CYNURENINE-3-MONOOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHOD OF USE THEREOF | |
| EP4121022A4 (en) | COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING CORONAVIRUS INFECTION | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| EP4460524A4 (en) | Compositions and methods for treatment of thyroid eye disease | |
| MA56607A1 (fr) | Méthodes de traitement de troubles dépressifs | |
| EA202190544A1 (ru) | Применение распадающихся в полости рта таблеток рилузола для лечения заболеваний | |
| EP4210750A4 (en) | Therapeutic methods and agents for the treatment of myocardial infarction | |
| EP4489746A4 (en) | Extended-release pharmaceutical compositions for the treatment of eye conditions | |
| EP4215531A4 (en) | COMPOUND FOR PREVENTING AND TREATING LIVER DISEASES AND ITS PHARMACEUTICAL USE | |
| MA58093B1 (fr) | Nouveaux analogues d'insuline et leurs utilisations | |
| ATE499933T1 (de) | Verwendung von betain zur behandlung von claudicatio intermittens | |
| MA39448B1 (fr) | (r)-pirlindole et ses sels pharmaceutiquement acceptables destinés à un usage médical | |
| MX2020007941A (es) | Metodo para prevenir o tratar enfermedad de alzheimer. | |
| DE60306503D1 (de) | Statin-therapie zur verbesserung der aufrechterhaltung der kognitiven funktion | |
| EP4103179A4 (en) | Combination therapy for treating amyotrophic lateral using pridopidine and another active agent |